A Phase 3 interventional study of Sarilumab SAR153191 (REGN88) and Placebo (for sarilumab) in Rheumatoid Arthritis, sponsored by Sanofi. Completed at 96 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-01-30.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 43rd largest by enrollment, is one of 2 that started in 2014, is one of 47 in phase 3, and was the 81st registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Keio University · Sites in Japan
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Konkuk University Medical Center · Sites in Korea, Republic of
Ages 19+
Medical University of Vienna · Sites in Austria
Ages 18–99
By country, each count listing its studies:
Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 20 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 12 · Phase 3 48 · Phase 4 38
First in 1998; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 243 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 130 across the 113 interventional studies. Of the 93 that completed or were terminated, 58 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 113 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
36 studies in Arthritis, Rheumatoid by Sanofi: 2 open now, 2 under way, none of them phase 3. Of 34 finished, 14 (41%) have results posted.
Among the 36 studies in Arthritis, Rheumatoid by Sanofi, this one is the 13th largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2014, is one of 9 in phase 3, and was the 22nd registered.
Sanofi’s Arthritis, Rheumatoid studies by the year they started, since 2002.
3 of the studies testing methotrexate in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05353829Region VästerbottenMethotrexate in Patients with Early Rheumatoid Arthritis | 2026-12-31 |
| NCT06590090XBiotech, Inc.Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | 2027-01-15 |
| NCT06649136Medical University of ViennaMethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients With Active Rheumatoid Arthritis | 2027-06-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, from their registry updates:
Among Sanofi’s 36 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
-To demonstrate that sarilumab added to methotrexate (MTX) reduce signs and symptoms of rheumatoid arthritis (RA) in Japanese RA participants with an inadequate response to MTX.
Secondary Objective:
-To assess the safety of sarilumab added to MTX in Japanese RA participants with an inadequate response to MTX.
The total duration of study was expected up to 62 weeks (screening period of 4 weeks, treatment period of 52 weeks, and a 6-week post treatment observation).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Sarilumab 150 mg subcutaneous (SC) injection once every 2 weeks (q2w) in combination with MTX and folic acid in double-blind period up to Week 24 followed by single-blind period in which participants continued with the same treatment up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits \[at least 4 weeks apart\] in either tender joint count \[TJC\] or swollen joint count \[SJC\], or with any other clear lack of efficacy based on investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
Drug: Sarilumab SAR153191 (REGN88) · Drug: Methotrexate · Drug: Folic acid
Sarilumab 200 mg SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by single-blind period in which participants continued with the same treatment up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits \[at least 4 weeks apart\] in either TJC or SJC, or with any other clear lack of efficacy based on investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
Drug: Sarilumab SAR153191 (REGN88) · Drug: Methotrexate · Drug: Folic acid
Placebo (for sarilumab) SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by a single-blind period in which participants were switched and received sarilumab 150 mg SC injection q2w in combination with MTX and folic acid up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits \[at least 4 weeks apart\] in either TJC or SJC, or with any other clear lack of efficacy based on Investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
Drug: Sarilumab SAR153191 (REGN88) · Other: Placebo (for sarilumab) · Drug: Methotrexate · Drug: Folic acid
Placebo (for sarilumab) SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by a single-blind period in which participants were switched and received sarilumab 200 mg SC injection q2w in combination with MTX and folic acid up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits \[at least 4 weeks apart\] in either TJC or SJC, or with any other clear lack of efficacy based on Investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
Drug: Sarilumab SAR153191 (REGN88) · Other: Placebo (for sarilumab) · Drug: Methotrexate · Drug: Folic acid
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Dispensed according to local practice.
Dispensed according to local practice.
Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response at Week 24
American College of Rheumatology (ACR) response is a composite rating scale that includes 7 variables: tender joints count (TJC \[68 joints\]); Swollen joints count (SJC \[66 joints\]); levels of an acute phase reactant (high sensitivity C-reactive protein \[hs-CRP level\]); participant's assessment of pain (measured on 0 \[no pain\]-100 mm \[worst pain\] visual analog scale \[VAS\]); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by health assessment questionnaire disability index \[HAQ-DI\], with scoring range of 0 \[better health\] - 3 \[worst health\]). ACR20 response was defined as achieving at least 20% improvement in both TJC and SJC, and at least 20% improvement in at least 3 of the 5 other assessments.
Time frame: Week 24
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, In-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Any AEs that developed or worsened or became serious during double-blind on-treatment period, single-blind on-treatment period up to 6-week post-treatment follow-up period (up to Week 58) were considered treatment-emergent.
Time frame: For placebo arm: Baseline up to Week 24; For sarilumab 150 mg/150 mg, sarilumab 200 mg/200 mg and sarilumab rescue arm: Baseline up to Week 58; For placebo/sarilumab 150 mg and placebo/sarilumab 200 mg arm: Week 25 up to Week 58
Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities
Criteria for potentially clinically significant vital sign abnormalities: * Systolic blood pressure supine (SBP\[S\]): \<=95 mmHg and decrease from baseline (DFB) \>=20 mmHg; \>=160 mmHg and increase from baseline (IFB) \>=20 mmHg * Diastolic blood pressure supine (DBP\[S\]): \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB \>=10 mmHg * Orthostatic systolic blood pressure (SBP\[O\]): \<=-20 mmHg * Orthostatic diastolic blood pressure (DBP\[O\]): \<=-10 mmHg * Heart rate supine (HR\[S\]): \<=50 beats per minute (bpm) and DFB \>=20 bpm; \>=120 bpm and IFB \>=20 bpm * Weight: \>=5% DFB; \>=5% IFB
Time frame: For placebo arm: Baseline up to Week 24; For sarilumab 150 mg/150 mg, sarilumab 200 mg/200 mg and sarilumab rescue arm: Baseline up to Week 58; For placebo/sarilumab 150 mg and placebo/sarilumab 200 mg arm: Week 25 up to Week 58
Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities
Criteria for potentially clinically significant ECG abnormalities: * PR Interval: \>200 millisecond (ms); \>200 ms and IFB \>=25%; \>220 ms; \>220 ms and IFB \>=25%; \>240 ms; \>240 ms and IFB \>=25% * QRS Interval: \>110 ms; \>110 ms and IFB \>=25%; \>120 ms; \>120 ms and IFB \>=25% * QT Interval: \>500 ms * QTc Bazett (QTc B): \>450 ms; 480 ms; 500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms * QTc Fridericia (QTc F): \>450 ms; 480 ms; 500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms
Time frame: For placebo arm: Baseline up to Week 24; For sarilumab 150 mg/150 mg, sarilumab 200 mg/200 mg and sarilumab rescue arm: Baseline up to Week 58; For placebo/sarilumab 150 mg and placebo/sarilumab 200 mg arm: Week 25 up to Week 58
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters
Criteria for potentially clinically significant abnormalities: * Hemoglobin: \<=115 g/L (Male\[M\]) or \<=95 g/L (Female\[F\]); \>=185 g/L (M) or \>=165 g/L (F); DFB \>=20 g/L * Hematocrit: \<=0.37 v/v (M) or \<=0.32 v/v (F); \>=0.55 v/v (M) or \>=0.5 v/v (F) * Red blood cells (RBC): \>=6 Tera/L * Platelets: \<50 Giga/L; \>=50 and \<100 Giga/L; \>=700 Giga/L * White blood cells (WBC): \<3.0 Giga/L (Non-Black\[NB\]) or \<2.0 Giga/L (Black\[B\]); \>=16.0 Giga/L * Neutrophils: \<1.5 Giga/L (NB) or \<1.0 Giga/L (B); \<1.0 Giga/L * Lymphocytes: \<0.5 Giga/L; \>=0.5 Giga/L and \< lower limit of normal (LLN); \>4.0 Giga/L * Monocytes: \>0.7 Giga/L * Basophils: \>0.1 Giga/L * Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L)
Time frame: For placebo arm: Baseline up to Week 24; For sarilumab 150 mg/150 mg, sarilumab 200 mg/200 mg and sarilumab rescue arm: Baseline up to Week 58; For placebo/sarilumab 150 mg and placebo/sarilumab 200 mg arm: Week 25 up to Week 58
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Metabolic Parameters
Criteria for potentially clinically significant abnormalities: * Glucose: \<=3.9 mmol/L and \<LLN; \>=11.1 mmol/L unfasted or \>=7 mmol/L fasted * Hemoglobin A1c (HbA1c): \>8% * Total cholesterol: \>=6.2 mmol/L; \>=7.74 mmol/L * LDL cholesterol: \>=4.1 mmol/L; \>=4.9 mmol/L * Triglycerides: \>=4.6 mmol/L; \>=5.6 mmol/L
Time frame: For placebo arm: Baseline up to Week 24; For sarilumab 150 mg/150 mg, sarilumab 200 mg/200 mg and sarilumab rescue arm: Baseline up to Week 58; For placebo/sarilumab 150 mg and placebo/sarilumab 200 mg arm: Week 25 up to Week 58
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes
Criteria for potentially clinically significant abnormalities: * Sodium: \<=129 mmol/L; \>=160 mmol/L * Potassium: \<3 mmol/L; \>=5.5 mmol/L * Chloride: \<80 mmol/L; \>115 mmol/L
Time frame: For placebo arm: Baseline up to Week 24; For sarilumab 150 mg/150 mg, sarilumab 200 mg/200 mg and sarilumab rescue arm: Baseline up to Week 58; For placebo/sarilumab 150 mg and placebo/sarilumab 200 mg arm: Week 25 up to Week 58
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Function Parameters
Criteria for potentially clinically significant abnormalities: * Creatinine: \>=150 micromol/L; \>=30% change from baseline; \>=100% change from baseline * Creatinine clearance: \<15 mL/min; \>=15 to \<30 mL/min; \>=30 to \< 60 mL/min; \>=60 to \<90 mL/min * Blood urea nitrogen: \>=17 mmol/L * Uric acid: \<120 micromol/L; \>408 micromol/L
Time frame: For placebo arm: Baseline up to Week 24; For sarilumab 150 mg/150 mg, sarilumab 200 mg/200 mg and sarilumab rescue arm: Baseline up to Week 58; For placebo/sarilumab 150 mg and placebo/sarilumab 200 mg arm: Week 25 up to Week 58
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters
Criteria for potentially clinically significant abnormalities: * Alanine Aminotransferase (ALT): \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN * Aspartate aminotransferase (AST): \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN * Alkaline phosphatase: \>1.5 ULN * Total bilirubin (TBILI): \>1.5 ULN; \>2 ULN * Conjugated bilirubin (CBILI): \>1.5 ULN; \>2 ULN * Unconjugated bilirubin: \>1.5 ULN; \>2 ULN * ALT and TBILI: ALT \>3 ULN and TBILI \>2 ULN * CBILI and TBILI: CBILI \>35% TBILI and TBILI \>1.5 ULN * Albumin: \<=25 g/L
Time frame: For placebo arm: Baseline up to Week 24; For sarilumab 150 mg/150 mg, sarilumab 200 mg/200 mg and sarilumab rescue arm : Baseline up to Week 58; For placebo/sarilumab 150 mg and placebo/sarilumab 200 mg arm: Week 25 up to Week 58
The study was conducted at 95 centers in Japan between 06 November 2014 and 28 October 2016. A total of 388 participants were screened, of whom 243 participants were randomized and 145 were screen failures.
| Milestone | Placebo | Sarilumab 150 mg/150 mg | Sarilumab 200 mg/200 mg | Placebo/Sarilumab 150 mg | Placebo/Sarilumab 200 mg |
|---|---|---|---|---|---|
| Started | 82 | 81 | 80 | 0 | 0 |
| Treated | 81 | 81 | 80 | 0 | 0 |
| Rescued | 44 | 6 | 8 | 0 | 0 |
| Completed | 71 | 74 | 70 | 0 | 0 |
| Not completed | 11 | 7 | 10 | 0 | 0 |
| Withdrew: Adverse event | 5 | 6 | 8 | 0 | 0 |
| Withdrew: Lack of efficacy | 5 | 1 | 2 | 0 | 0 |
| Withdrew: Randomized but not treated | 1 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | Sarilumab 150 mg/150 mg | Sarilumab 200 mg/200 mg | Placebo/Sarilumab 150 mg | Placebo/Sarilumab 200 mg |
|---|---|---|---|---|---|
| Started | 0 | 74 | 70 | 34 | 37 |
| Completed | 0 | 66 | 68 | 33 | 31 |
| Not completed | 0 | 8 | 2 | 1 | 6 |
| Withdrew: Adverse event | 0 | 7 | 1 | 1 | 6 |
| Withdrew: Lack of efficacy | 0 | 1 | 1 | 0 | 0 |
American College of Rheumatology (ACR) response is a composite rating scale that includes 7 variables: tender joints count (TJC \[68 joints\]); Swollen joints count (SJC \[66 joints\]); levels of an acute phase reactant (high sensitivity C-reactive protein \[hs-CRP level\]); participant's assessment of pain (measured on 0 \[no pain\]-100 mm \[worst pain\] visual analog scale \[VAS\]); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by health assessment questionnaire disability index \[HAQ-DI\], with scoring range of 0 \[better health\] - 3 \[worst health\]). ACR20 response was defined as achieving at least 20% improvement in both TJC and SJC, and at least 20% improvement in at least 3 of the 5 other assessments.
| percentage of participants | Placebo | Sarilumab 150 mg | Sarilumab 200 mg |
|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response at Week 24 | 14.8 | 67.9 | 57.5 |
AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, In-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Any AEs that developed or worsened or became serious during double-blind on-treatment period, single-blind on-treatment period up to 6-week post-treatment follow-up period (up to Week 58) were considered treatment-emergent.
| participants | Placebo | Sarilumab 150 mg/150 mg | Sarilumab 200 mg/200 mg | Placebo/Sarilumab 150 mg | Placebo/Sarilumab 200 mg | Sarilumab Rescue |
|---|---|---|---|---|---|---|
| Treatment Emergent AEs | 49 | 76 | 71 | 12 | 13 | 54 |
| Treatment Emergent SAEs | 6 | 8 | 5 | 0 | 2 | 4 |
Criteria for potentially clinically significant vital sign abnormalities: * Systolic blood pressure supine (SBP\[S\]): \<=95 mmHg and decrease from baseline (DFB) \>=20 mmHg; \>=160 mmHg and increase from baseline (IFB) \>=20 mmHg * Diastolic blood pressure supine (DBP\[S\]): \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB \>=10 mmHg * Orthostatic systolic blood pressure (SBP\[O\]): \<=-20 mmHg * Orthostatic diastolic blood pressure (DBP\[O\]): \<=-10 mmHg * Heart rate supine (HR\[S\]): \<=50 beats per minute (bpm) and DFB \>=20 bpm; \>=120 bpm and IFB \>=20 bpm * Weight: \>=5% DFB; \>=5% IFB
| participants | Placebo | Sarilumab 150 mg/150 mg | Sarilumab 200 mg/200 mg | Placebo/Sarilumab 150 mg | Placebo/Sarilumab 200 mg | Sarilumab Rescue |
|---|---|---|---|---|---|---|
| SBP(S) <=95 mmHg and DFB >=20 mmHg | 2 | 4 | 1 | 0 | 0 | 0 |
| SBP(S) >=160 mmHg and IFB >=20 mmHg | 2 | 5 | 5 | 0 | 1 | 8 |
| DBP(S) <=45 mmHg and DFB >=10 mmHg | 1 | 1 | 1 | 0 | 0 | 0 |
| DBP(S)>=110 mmHg and IFB >=10 mmHg | 0 | 1 | 0 | 0 | 0 | 0 |
| SBP(O) <=-20 mmHg | 8 | 21 | 23 | 2 | 2 | 12 |
| DBP(O) <=-10 mmHg | 8 | 17 | 12 | 0 | 1 | 10 |
| HR(S) <=50 bpm and DFB >=20 bpm | 0 | 4 | 1 | 0 | 0 | 1 |
| HR(S) >=120 bpm and IFB >=20 bpm | 1 | 0 | 0 | 0 | 0 | 0 |
| Weight >=5% DFB | 5 | 5 | 7 | 0 | 0 | 4 |
| Weight >=5% IFB | 5 | 31 | 27 | 7 | 6 | 15 |
Criteria for potentially clinically significant ECG abnormalities: * PR Interval: \>200 millisecond (ms); \>200 ms and IFB \>=25%; \>220 ms; \>220 ms and IFB \>=25%; \>240 ms; \>240 ms and IFB \>=25% * QRS Interval: \>110 ms; \>110 ms and IFB \>=25%; \>120 ms; \>120 ms and IFB \>=25% * QT Interval: \>500 ms * QTc Bazett (QTc B): \>450 ms; 480 ms; 500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms * QTc Fridericia (QTc F): \>450 ms; 480 ms; 500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms
| participants | Placebo | Sarilumab 150 mg/150 mg | Sarilumab 200 mg/200 mg | Placebo/Sarilumab 150 mg | Placebo/Sarilumab 200 mg | Sarilumab Rescue |
|---|---|---|---|---|---|---|
| PR Interval >200 ms | 6 | 9 | 5 | 0 | 2 | 6 |
| PR Interval >200 ms and IFB >=25% | 0 | 1 | 0 | 0 | 0 | 0 |
| PR Interval >220 ms | 3 | 4 | 2 | 0 | 1 | 2 |
| PR Interval >220 ms and IFB >=25% | 0 | 1 | 0 | 0 | 0 | 0 |
| PR Interval >240 ms | 2 | 1 | 0 | 0 | 1 | 2 |
| PR Interval >240 ms and IFB >=25% | 0 | 0 | 0 | 0 | 0 | 0 |
| QRS Interval >110 ms | 2 | 2 | 2 | 1 | 1 | 3 |
| QRS Interval >110 ms and IFB >=25% | 0 | 0 | 0 | 0 | 0 | 1 |
| QRS Interval >120 ms | 2 | 2 | 1 | 1 | 1 | 2 |
| QRS Interval >120 ms and IFB >=25% | 0 | 0 | 0 | 0 | 0 | 1 |
| QT Interval >500 ms | 1 | 0 | 1 | 0 | 0 | 3 |
| QTc B >450 ms | 12 | 16 | 22 | 2 | 3 | 18 |
| QTc B >480 ms | 0 | 2 | 2 | 0 | 1 | 2 |
| QTc B >500 ms | 0 | 0 | 0 | 0 | 0 | 0 |
| QTc B IFB >30 and <=60 ms | 2 | 2 | 2 | 0 | 1 | 5 |
| QTc B IFB >60 ms | 0 | 0 | 0 | 0 | 0 | 0 |
| QTc F>450 ms | 7 | 11 | 14 | 0 | 2 | 12 |
| QTc F>480 ms | 0 | 0 | 0 | 0 | 1 | 1 |
| QTc F>500 ms | 0 | 0 | 0 | 0 | 0 | 0 |
| QTc F IFB >30 and <=60 ms | 4 | 4 | 3 | 0 | 1 | 3 |
| QTc F IFB >60 ms | 0 | 0 | 0 | 0 | 0 | 0 |
Criteria for potentially clinically significant abnormalities: * Hemoglobin: \<=115 g/L (Male\[M\]) or \<=95 g/L (Female\[F\]); \>=185 g/L (M) or \>=165 g/L (F); DFB \>=20 g/L * Hematocrit: \<=0.37 v/v (M) or \<=0.32 v/v (F); \>=0.55 v/v (M) or \>=0.5 v/v (F) * Red blood cells (RBC): \>=6 Tera/L * Platelets: \<50 Giga/L; \>=50 and \<100 Giga/L; \>=700 Giga/L * White blood cells (WBC): \<3.0 Giga/L (Non-Black\[NB\]) or \<2.0 Giga/L (Black\[B\]); \>=16.0 Giga/L * Neutrophils: \<1.5 Giga/L (NB) or \<1.0 Giga/L (B); \<1.0 Giga/L * Lymphocytes: \<0.5 Giga/L; \>=0.5 Giga/L and \< lower limit of normal (LLN); \>4.0 Giga/L * Monocytes: \>0.7 Giga/L * Basophils: \>0.1 Giga/L * Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L)
| participants | Placebo | Sarilumab 150 mg/150 mg | Sarilumab 200 mg/200 mg | Placebo/Sarilumab 150 mg | Placebo/Sarilumab 200 mg | Sarilumab Rescue |
|---|---|---|---|---|---|---|
| Hemoglobin <=115 g/L (M) or <=95 g/L (F) | 9 | 4 | 5 | 0 | 1 | 5 |
| Hemoglobin >=185 g/L (M) or >=165 g/L (F) | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin DFB >=20 g/L | 4 | 0 | 3 | 0 | 0 | 1 |
| Hematocrit <=0.37 v/v (M) or <=0.32 v/v (F) | 17 | 10 | 14 | 0 | 3 | 6 |
| Hematocrit >=0.55 v/v (M) or >=0.5 v/v (F) | 0 | 0 | 0 | 0 | 0 | 0 |
| RBC >=6 Tera/L | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets <50 Giga/L | 0 | 1 | 0 | 0 | 0 | 0 |
| Platelets >=50 and <100 Giga/L | 0 | 2 | 4 | 0 | 0 | 1 |
| Platelets >=700 Giga/L | 1 | 0 | 0 | 0 | 0 | 0 |
| WBC <3.0 Giga/L (NB) or <2.0 Giga/L (B) | 0 | 30 | 23 | 5 | 6 | 17 |
| WBC >=16.0 Giga/L | 0 | 5 | 5 | 0 | 0 | 2 |
| Neutrophils <1.5 Giga/L (NB) or <1.0 Giga/L (B) | 0 | 31 | 24 | 5 | 6 | 18 |
| Neutrophils <1.0 Giga/L | 0 | 11 | 6 | 3 | 0 | 8 |
| Lymphocytes <0.5 Giga/L | 3 | 6 | 3 | 1 | 2 | 1 |
| Lymphocytes >=0.5 Giga/L and <LLN | 23 | 29 | 32 | 4 | 2 | 18 |
| Lymphocytes >4.0 Giga/L | 0 | 0 | 0 | 0 | 0 | 0 |
| Monocytes >0.7 Giga/L | 9 | 10 | 7 | 0 | 2 | 3 |
| Basophils >0.1 Giga/L | 6 | 11 | 9 | 1 | 0 | 9 |
| Eosinophils>0.5 Giga/L or >ULN(if ULN>=0.5 Giga/L) | 1 | 2 | 1 | 1 | 0 | 2 |
Criteria for potentially clinically significant abnormalities: * Glucose: \<=3.9 mmol/L and \<LLN; \>=11.1 mmol/L unfasted or \>=7 mmol/L fasted * Hemoglobin A1c (HbA1c): \>8% * Total cholesterol: \>=6.2 mmol/L; \>=7.74 mmol/L * LDL cholesterol: \>=4.1 mmol/L; \>=4.9 mmol/L * Triglycerides: \>=4.6 mmol/L; \>=5.6 mmol/L
| participants | Placebo | Sarilumab 150 mg/150 mg | Sarilumab 200 mg/200 mg | Placebo/Sarilumab 150 mg | Placebo/Sarilumab 200 mg | Sarilumab Rescue |
|---|---|---|---|---|---|---|
| Glucose <=3.9 mmol/L and <LLN | 0 | 0 | 2 | 1 | 1 | 2 |
| Glucose>=11.1 mmol/L unfasted or >=7 mmol/L fasted | 3 | 8 | 4 | 0 | 0 | 1 |
| HbA1c >8% | 0 | 0 | 0 | 0 | 0 | 0 |
| Total cholesterol >=6.2 mmol/L | 9 | 40 | 32 | 4 | 2 | 17 |
| Total cholesterol >=7.74 mmol/L | 0 | 7 | 5 | 0 | 1 | 3 |
| LDL cholesterol >=4.1 mmol/L | 3 | 20 | 17 | 3 | 1 | 7 |
| LDL cholesterol >=4.9 mmol/L | 0 | 4 | 6 | 0 | 1 | 2 |
| Triglycerides >=4.6 mmol/L | 0 | 0 | 3 | 0 | 1 | 2 |
| Triglycerides >=5.6 mmol/L | 0 | 0 | 3 | 0 | 1 | 2 |
Criteria for potentially clinically significant abnormalities: * Sodium: \<=129 mmol/L; \>=160 mmol/L * Potassium: \<3 mmol/L; \>=5.5 mmol/L * Chloride: \<80 mmol/L; \>115 mmol/L
| participants | Placebo | Sarilumab 150 mg/150 mg | Sarilumab 200 mg/200 mg | Placebo/Sarilumab 150 mg | Placebo/Sarilumab 200 mg | Sarilumab Rescue |
|---|---|---|---|---|---|---|
| Sodium <=129 mmol/L | 0 | 0 | 1 | 0 | 0 | 0 |
| Sodium >=160 mmol/L | 0 | 0 | 1 | 0 | 0 | 1 |
| Potassium <3 mmol/L | 0 | 0 | 1 | 0 | 0 | 0 |
| Potassium >=5.5 mmol/L | 0 | 0 | 2 | 0 | 1 | 0 |
| Chloride <80 mmol/L | 0 | 0 | 0 | 0 | 0 | 0 |
| Chloride >115 mmol/L | 0 | 0 | 0 | 0 | 0 | 1 |
Criteria for potentially clinically significant abnormalities: * Creatinine: \>=150 micromol/L; \>=30% change from baseline; \>=100% change from baseline * Creatinine clearance: \<15 mL/min; \>=15 to \<30 mL/min; \>=30 to \< 60 mL/min; \>=60 to \<90 mL/min * Blood urea nitrogen: \>=17 mmol/L * Uric acid: \<120 micromol/L; \>408 micromol/L
| participants | Placebo | Sarilumab 150 mg/150 mg | Sarilumab 200 mg/200 mg | Placebo/Sarilumab 150 mg | Placebo/Sarilumab 200 mg | Sarilumab Rescue |
|---|---|---|---|---|---|---|
| Creatinine >=150 micromol/L | 0 | 1 | 1 | 0 | 1 | 0 |
| Creatinine >=30% change from baseline | 5 | 18 | 22 | 0 | 4 | 17 |
| Creatinine >=100% change from baseline | 0 | 1 | 1 | 0 | 1 | 0 |
| Creatinine clearance <15 mL/min | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine clearance >=15 to <30 mL/min | 0 | 1 | 0 | 0 | 1 | 0 |
| Creatinine clearance >=30 to <60 mL/min | 6 | 12 | 14 | 0 | 2 | 7 |
| Creatinine clearance >=60 to <90 mL/min | 41 | 45 | 42 | 7 | 5 | 35 |
| Blood urea nitrogen >=17 mmol/L | 0 | 0 | 0 | 0 | 1 | 0 |
| Uric acid <120 micromol/L | 0 | 1 | 2 | 0 | 0 | 0 |
| Uric acid >408 micromol/L | 8 | 13 | 14 | 3 | 3 | 5 |
Criteria for potentially clinically significant abnormalities: * Alanine Aminotransferase (ALT): \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN * Aspartate aminotransferase (AST): \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN * Alkaline phosphatase: \>1.5 ULN * Total bilirubin (TBILI): \>1.5 ULN; \>2 ULN * Conjugated bilirubin (CBILI): \>1.5 ULN; \>2 ULN * Unconjugated bilirubin: \>1.5 ULN; \>2 ULN * ALT and TBILI: ALT \>3 ULN and TBILI \>2 ULN * CBILI and TBILI: CBILI \>35% TBILI and TBILI \>1.5 ULN * Albumin: \<=25 g/L
| participants | Placebo | Sarilumab 150 mg/150 mg | Sarilumab 200 mg/200 mg | Placebo/Sarilumab 150 mg | Placebo/Sarilumab 200 mg | Sarilumab Rescue |
|---|---|---|---|---|---|---|
| ALT >1 ULN and <=1.5 ULN | 3 | 17 | 24 | 3 | 6 | 16 |
| ALT >1.5 ULN and <=3 ULN | 7 | 24 | 19 | 4 | 4 | 9 |
| ALT >3 ULN and <=5 ULN | 6 | 11 | 5 | 2 | 0 | 4 |
| ALT >5 ULN and <=10 ULN | 0 | 1 | 2 | 0 | 1 | 2 |
| ALT >10 ULN and <=20 ULN | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT >20 ULN | 0 | 0 | 0 | 0 | 0 | 0 |
| AST >1 ULN and <=1.5 ULN | 7 | 34 | 32 | 6 | 8 | 22 |
| AST >1.5 ULN and <=3 ULN | 11 | 18 | 10 | 3 | 1 | 11 |
| AST >3 ULN and <=5 ULN | 1 | 5 | 2 | 1 | 1 | 3 |
| AST >5 ULN and <=10 ULN | 0 | 0 | 1 | 0 | 0 | 0 |
| AST >10 ULN and <=20 ULN | 0 | 0 | 0 | 0 | 0 | 0 |
| AST >20 ULN | 0 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase >1.5 ULN | 0 | 2 | 0 | 0 | 0 | 0 |
| TBILI >1.5 ULN | 0 | 1 | 2 | 1 | 0 | 3 |
| TBILI >2 ULN | 0 | 0 | 1 | 0 | 0 | 1 |
| CBILI >1.5 ULN | 0 | 0 | 0 | 0 | 0 | 1 |
| CBILI >2 ULN | 0 | 0 | 0 | 0 | 0 | 1 |
| Unconjugated bilirubin >1.5 ULN | 0 | 0 | 1 | 0 | 0 | 1 |
| Unconjugated bilirubin >2 ULN | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT >3 ULN and TBILI >2 ULN | 0 | 0 | 0 | 0 | 0 | 0 |
| CBILI >35% TBILI and TBILI >1.5 | 0 | 0 | 0 | 0 | 0 | 1 |
| Albumin <=25 g/L | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over For placebo arm: Baseline up to Week 24; For sarilumab 150 mg/150 mg, sarilumab 200 mg/200 mg and sarilumab rescue arm: Baseline up to Week 58; For placebo/sarilumab 150 mg and placebo/sarilumab 200 mg arm: Week 25 up to Week 58.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 6/81 (7.4%) | 35/81 (43.2%) |
| Sarilumab 150 mg/150 mg | — | 8/81 (9.9%) | 67/81 (82.7%) |
| Sarilumab 200 mg/200 mg | — | 5/80 (6.3%) | 59/80 (73.8%) |
| Placebo/Sarilumab 150 mg | — | 0/14 (0%) | 12/14 (85.7%) |
| Placebo/Sarilumab 200 mg | — | 2/15 (13.3%) | 13/15 (86.7%) |
| Sarilumab Rescue | — | 4/58 (6.9%) | 48/58 (82.8%) |
| Event | Placebo | Sarilumab 150 mg/150 mg | Sarilumab 200 mg/200 mg | Placebo/Sarilumab 150 mg | Placebo/Sarilumab 200 mg | Sarilumab Rescue |
|---|---|---|---|---|---|---|
| Pneumocystis jirovecii pneumoniaInfections and infestations | 0/81 | 1/81 | 0/80 | 0/14 | 1/15 | 0/58 |
| Lumbar spinal stenosisMusculoskeletal and connective tissue disorders | 0/81 | 0/81 | 0/80 | 0/14 | 1/15 | 0/58 |
| Venous thrombosis limbVascular disorders | 0/81 | 0/81 | 0/80 | 0/14 | 1/15 | 0/58 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 2/81 | 0/81 | 0/80 | 0/14 | 0/15 | 0/58 |
| LeukopeniaBlood and lymphatic system disorders | 0/81 | 0/81 | 0/80 | 0/14 | 0/15 | 1/58 |
| Gastroenteritis bacterialInfections and infestations | 0/81 | 0/81 | 0/80 | 0/14 | 0/15 | 1/58 |
| Pneumonia pneumococcalInfections and infestations | 0/81 | 0/81 | 0/80 | 0/14 | 0/15 | 1/58 |
| OsteoporosisMusculoskeletal and connective tissue disorders | 0/81 | 0/81 | 0/80 | 0/14 | 0/15 | 1/58 |
| Macular fibrosisEye disorders | 0/81 | 0/81 | 1/80 | 0/14 | 0/15 | 0/58 |
| Radius fractureInjury, poisoning and procedural complications | 0/81 | 0/81 | 1/80 | 0/14 | 0/15 | 0/58 |
| Event | Placebo | Sarilumab 150 mg/150 mg | Sarilumab 200 mg/200 mg | Placebo/Sarilumab 150 mg | Placebo/Sarilumab 200 mg | Sarilumab Rescue |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 12/81 | 27/81 | 23/80 | 5/14 | 4/15 | 19/58 |
| Alanine aminotransferase increasedInvestigations | 4/81 | 7/81 | 4/80 | 3/14 | 0/15 | 3/58 |
| NeutropeniaBlood and lymphatic system disorders | 0/81 | 10/81 | 9/80 | 2/14 | 1/15 | 6/58 |
| StomatitisGastrointestinal disorders | 3/81 | 6/81 | 8/80 | 2/14 | 1/15 | 7/58 |
| LeukopeniaBlood and lymphatic system disorders | 0/81 | 2/81 | 1/80 | 0/14 | 2/15 | 1/58 |
| DiarrhoeaGastrointestinal disorders | 0/81 | 2/81 | 2/80 | 0/14 | 2/15 | 4/58 |
| Upper respiratory tract infectionInfections and infestations | 4/81 | 8/81 | 7/80 | 0/14 | 0/15 | 6/58 |
| Injection site erythemaGeneral disorders | 0/81 | 8/81 | 7/80 | 1/14 | 0/15 | 5/58 |
| Hepatic function abnormalHepatobiliary disorders | 4/81 | 8/81 | 7/80 | 0/14 | 0/15 | 4/58 |
| EczemaSkin and subcutaneous tissue disorders | 1/81 | 7/81 | 4/80 | 1/14 | 0/15 | 3/58 |
Analysis was performed on randomized population which included all participants who had been allocated to a randomized treatment regardless of whether the treatment was actually administered.
| Age, Continuous(years) | Placebo | Sarilumab 150 mg/150 mg | Sarilumab 200 mg/200 mg | Total |
|---|---|---|---|---|
| Mean | 53.4 ± 11.5 | 56.1 ± 9.5 | 55.3 ± 11.0 | 54.9 ± 10.7 |
| Sex: Female, Male(Participants) | Placebo | Sarilumab 150 mg/150 mg | Sarilumab 200 mg/200 mg | Total |
|---|---|---|---|---|
| Female | 65 | 63 | 61 | 189 |
| Male | 17 | 18 | 19 | 54 |
The record gives a start of Nov 2014, a primary completion of Oct 2016 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2018, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methotrexate